SAM selects the target population on the following criteria:
Targeting vulnerability: SAM works with the poor and vulnerable communities who lack education, income, assets, status and access to healthcare.
Targeting pregnant, infants and children: SAM follows all pregnant women, infants and children under 5 years in the community.
Targeting reproductive age: For population stabilisation, SAM targets reproductive age group women and married couples between ages 18 and 49 years and adolescent girls from 10 to 19 years.
Targeting disease: SAM targets the families and contacts all TB patients, malnourished children and high-risk pregnant women.
SAM-ESP Innovation: SAM has developed a cost-effective platform for changing health behaviour ofa community. Health activists, in partnership with local public and private healthcare stakeholders, convert awareness to actionable knowledge. SAM has successfully used its Effective Social Persuasion Platform (SAM-ESP) in multiple locations. ESP relies on seven assumptions.
Also Read: Cancer Patients Get Meditation Session at HCG with Dozee
Behaviour modification is the least expensive way to reduce disease burden.

Health is an individual and community responsibility; ownership of this responsibility empowers a community to demand healthcare rights. A campaign to push health information may improve awareness but is not sufficient by itself. Awareness is just one of many steps to change behaviour. Other essential steps include: a sustained, intensive, repetitive campaign without a predefined end time-point, encouraging peer to peer nudge and a methodical transfer of ownership to the community leaders.

Messages scripted by the community encourages their ownership. Trained volunteer activists can lead and sustain the ESP without external help.

Also Read: Digital Diabetes Management Market

An established SAM-ESP platform can be used to address multiplehealth problems. SAM-ESP is not yetanother awareness building program. Awareness is often assumed to be equal to behaviour change. In practice, it is not true. Communication programs and prevalent awareness programs merely touch the surface without translating into significant behaviour change. SAM-ESP is a multi-step process, where awareness in just one of many steps for a sustainable behaviour change.

SAM promotes community ownership of both health and healthcare. SAM believes, that health is an individual and community responsibility and getting healthcare, as a right, has to be learned. SAM-ESP is a peoples’ program, which ensures that the health system is responsive and accountable.

Also Read: Snakebite: A Public Health Problem

SAM trains volunteer health activists who lead the program and develops a cadre of social entrepreneurs, who sell contraceptives, sanitary pads and nutritional products. SAM field workers are from the community where they live and work. They are available 24/7 and take health to the doorstep of the recipients. The program sets no predetermined end date; repetitive training continues till SAM meets the objectives.

The following steps describe its execution:

Organize, create structure and build leadership capacity: SAM has well-trained field staff and managers;the voluntary directors of the organization are professionals from healthcare and management. Each district has a manager, trainers, and supervisors who are selected from the local population. They receive intensive training not only in health issues but also in motivational techniques, training methods and leadership.

Develop messages: SAM believes that a good message should be simple without technical jargon, short with less than five points, easy to understand without explanation and emotionally connected with a local need. For better retention, a message could be in the form of a story, song or a slogan. Some messages should be created by the community to feel ownership.

Also Read: Health and Wellness Coach Platform for Industrial Workers

Train health activists: Master trainers train volunteer health activists to be responsible for village health issues. Training is repetitive and intense.

Teach people: SAM organizes the village into a healthcare community. Field supervisors motivate and mobilize villagers and discuss each topic of healthcare with a specific training module. SAM uses local community resources to create training material and health leaders script their own songs and slogans. Activists meet villagers repeatedly to discuss best practices. Repetitive training of health activists and villagers is essential.

Cooperation with public and private health systems: SAM establishes linkage with the local private and public health system. Utilizing all available public health resources is an essential component of the program. Public health workers are invited to all meetings. This linkage creates awareness, which improves demand of healthcare and encourages accountability.

Also Read: Cybercrime and Threats in 2019
Evaluation and improvement: Programs are monitored by community involvement and by participatory research action. Results lead tocourse correction.
Replicate: Solutions are validated and replicated in other locations.

Measuring impact: Each program starts with a baseline and finishes with an end-line evaluation. SAM defines objectives, activities, outputs and outcomes before the start of the program. They measure monthly progress against all these parameters.

Process of measuring impact is a four-step process:
Data Collection at community level: The field workers collect data during house visits and community meetings. They upload it on a smartphone.
Data review at block level: Field officers collate and review data every month at a block level. They validate it through client interaction.

Data validation at district level: SAM validates data through a monitor and evaluation protocol which includes field visits, focus groups and comparison with public health data. SAM compares outcomes and impact with similar programs run by the government and other private organisations.

External agency evaluation: Periodically, SAM engages external agencies to evaluate its work. The funding partners also send external evaluators to check the progress and impact.

Direct impact: Since inception, SAM has trained 37,000 volunteer health activists who live in the villages and are available to the community. SAM has directly impacted over 1,150,000 million people through maternal, child health, population stabilisation and TB control programs.

Also Read: Tiny Robot Caterpillar Deliver Drugs

Through maternal, child health and population stabilization programs, SAM has directly impacted: 530,000 women and over approximately 100,000 infants. SAM follows all (100%) pregnant women in the villages and has reduced maternal mortality by 90% and infant mortality by 60%. In some places, SAM has done even better. In the past 6 years, in 167 villages of Gadag, Karnataka; maternal mortality rate has decreased to 15.8 from 364 and the Infant mortality rate has decreased to 5 from 46.

Through population stabilizations program, the marriage of girls under 18 years of age has decreased to almost zero. Contraceptive use has increased from 28% to 62% and supplychain management has reduced the unmet need for contraception from 10.8 % to 2% been running in 700 villages. 287,042 people have participated in 14,552 community meetings. 13,973 people have had sputum tested. Sputum was positive for TB in 1329 people and 14 had multiple drug resistant TB. All received supervised treatment. SAM has directly helped with education and surveillance of 130,000 contacts of TB patients and helped another 317,000 community members with awareness program. TB detection rate has improved 3.7 times.

Also Read: National Ageing Center Coming in New Delhi

Indirect impact: SAM estimates that approximately 0.9 to 1 million people, who did not actively participate in its programs, became aware of the benefits from those who attended our programs.

Women feel empowered, which has opened their minds to many choices in life. They express their opinions freely. Men and elderly women, who were suspicious and objected to their women attending public meetings, have mellowed their resistance and have even become enablers. Girls attend school more regularly and the number of girls attending college has increased. Adolescents participation has increased. Public health system and their workers are more responsive to public demand.Local elected politicians are responsive.

Also Read: Religious People Live Four Years Longer Than Atheists

Discussion: Multiple theories have attempted to explain the health behaviour of individuals. The most popular is the Health Belief Model (HBM), which was developed about 40 years back. It postulates that people make healthcare decisions based on perceived susceptibility to disease and consequences. The response is tempered by perceived benefits of action and with a belief that benefits outweigh risks. While this theory, like other theories, builds a plausible reference point to explain behaviour, it gives no guidance for modification of individual behaviour.

Theory of Planned Behaviour suggests that a person should be empowered with ability (self-efficacy) to change behaviour. The person should believe that the behaviour will improve his health and is socially approved. It has also been recommended that principles of marketing could be applied to a social cause, where the product to be sold is behaviour change.

Also Read: A trip to Copenhagen for Bio-Europe 2018

SAM model comes close to a hybrid variety of HBM, building self-efficacy and social marketing. SAM tries todevelop social efficacy through the agency of health activists by using techniques similar to social marketing. SAM Effective Social Persuasion is a people’s platform, which needs further elucidation and expansion. SAM is looking to use entertainment education or gamification for behaviour modification and use of technology in early detection of noncommunicable diseases. SAM seeks collaboration with others for mutual learning, sharing resources and scaling-up the program in vulnerable population.

About the author

Dr. Shiban Ganju is the Chairman of Atrimed Pharmaceuticals and Founder of Save A Mother Foundation, USA. He has dedicated his life to healthcare. Dr. Ganju graduated from AIIMS New Delhi and received advanced training in Internal Medicine and Gastroenterology both in India and USA. He is a consultant specializing in gastroenterology, liver disease and nutrition in hospitals in the greater Chicago area. His commitment to and understanding of how to drive improvements in health outcomes has benefitted big strata of society.

This is because of the singular and unique ability of the TB bacterium to hide inside the human body in a dormant state without causing the disease or revealing any outward symptoms. Such cases are classified as latent TB infections and can be revealed by diagnostic tests in healthy seemingly uninfected individuals. Studies indicate that close to 40% of the Indian population is positive for latent TB and without treatment 5%-10% of these will develop active TB at some point in their lives. Unfortunately, due to the high burden of TB in India, the detection and treatment of latent TB are not prioritized, resulting in a huge reservoir of dormant and potentially infectious bacteria primed to emerge under favorable conditions.

In 2017, 10 million people were infected with TB and 1.6 million died worldwide, surpassing AIDS as the world’s leading cause of death due to an infectious disease. WHO has designated March 24t has the World TB Day to raise public awareness about TB and its deleterious effects on health, society and the economy. In 2015, it began to implement the ‘End TB Strategy’ which envisions a world free of TB with zero TB related deaths and zero incidences of the disease. In order to do this, WHO aims to support and promote a patient-centric approach to care and prevention, encourage proactive policies and support systems by involving the government and private sector healthcare and finally intensify research and innovation in the field of TB treatment, prevention, and diagnosis. The Government of India has instituted a similar strategy, the Revised National Tuberculosis Control Program (RNTCP). RNTCP involves adopting WHO guidelines of Direct Observation Therapy (DOT) to the Indian scenario and includes direct monitoring and administration of anti-TB drugs to the patient, rapid TB diagnosis and treatment, and increased partnership between public and private healthcare systems. RNTCP’s objective is to eliminate TB by 2025. The plan outlines four directives – Detect, Treat, Prevent and Build and includes a system for free and sensitive diagnostic tests for TB, screening of the high-risk population, free TB drugs for all patients, implementation of a uniform treatment regimen, increased social support and monitoring and treatment of latent TB. Finally, the plan will work towards translation of political commitment to action through strengthening support structures for surveillance, research, and innovation.

Several technological innovations have facilitated easier and improved patient monitoring, such as 99DOTS which is a low-cost solution for improving patient compliance during TB treatment. Patients using 99DOTS receive medication in specially packaged blister packs. Dispensation of a dose reveals a hidden and unique phone number that the patients can call for free and confirm that the medication has been taken. In this way, remote monitoring of patient compliance has been made possible. Several digital adherence technologies have also been developed as an electronic way to monitor medication and provide reminders. These include digital pill boxes (evriMED, Wisepill, etc.) that are given to patients with their medication inside. The digital boxes provide visual cues such as colored LED lights which turn on and remind the patient of the dose and the medicine that is due. These boxes can also record medication events in real time by logging the opening of the box for each dose, allowing for real-time monitoring of patient compliance. Pilot studies are also underway in the US for ingestible sensors that are embedded inside each pill, which transmits information that the pill was consumed upon activation inside the patient’s stomach. However, the cost of such technology is yet to be estimated and given WHO and Govt. of India goals to reduce the economic burden of TB, cost-effective ingestible sensors may remain only a distant possibility.

Also Read:
Health Of The Indian States
Healthy Lives: Everyone, Everywhere

Risk Factors for TB

Being primarily a respiratory disease, TB is disseminated by airborne infection as the bacteria is exhaled from an infected individual and inhaled by another. This often happens in poorly ventilated and over-crowded settings typically seen in cramped housing where the disease can spread like wildfire. Indeed, earlier TB was thought to be hereditary as it used to wipe out entire households. Weakening of the body’s immune system due to age, substance abuse, air pollution, diabetes, HIV infection, and malnutrition, among others, play a major role in increasing susceptibility to TB. Its spread is seen across the socio-economic strata. As Dr. Zarir Udwadia, one of the world’s leading pulmonologists puts it, “TB does not distinguish between the chauffeur driving the Mercedes and the CEO sitting at the back!”

Detection and Diagnosis of TB

One of the main challenges in the fight against TB is the very first step of diagnosis. Millions of TB cases go undetected and unrecorded all over the world due to the shortcomings of technology. Conventional TB diagnosis is performed by sputum smear microscopy, wherein the sputum of the patient is examined under a microscope for TB bacilli. However, this approach is only 36-43% sensitive which means that many cases of TB infection are missed by this method.

Sputum smear microscopy also suffers from false positives, as some non-TB bacilli may also pick up the TB specific stain. Therefore, a positive sputum smear needs to be confirmed by culturing the bacilli obtained from the sputum in the lab, which can then be tested to confirm TB. Unfortunately, growing patient strains and analyzing them requires resources and technical expertise that are not available in most of the high prevalence countries. In addition, growth-based confirmation of TB positivity takes a minimum of 21 days since the growth rate of the bacilli is extremely slow.

A third technique, which involves the detection of TB DNA using polymerase chain reaction (PCR) and named Xpert MTB/RIF promises results of sample positivity within 2 hours and is currently the gold standard in PCR based TB diagnosis. However, this system suffers from high costs per assay and the requirement for infrastructure and constant electricity, which are not available in many cases.

Treatment for TB

Active TB infections are treated with a standard 6-9 months treatment regimen involving four antibiotics: rifampin, isoniazid, ethambutol, and pyrazinamide for varying durations. This treatment duration is one of the longest for bacterial infectious disease, second only to the treatment of leprosy. Side effects like itching, rashes, fever, nausea, diarrhea and reddish/orange discoloration of body fluids including urine, tears, and saliva is another cause of worry which takes a physical, emotional and mental toll on the patient.

Since most infected individuals begin to feel better after a few weeks of treatment and the length and side-effects of the drug treatment are arduous, many patients stop the treatment prematurely or skip doses. Rampant patient non-compliance when it comes to the completion of anti-TB therapy is one of the main factors for the emergence of a more severe form of the disease, one which is resistant to common drugs! This is a big reason for TB reactivation and the continued prevalence of this disease even though it is completely curable in most cases.

Drug resistance in TB has been known since the first antibiotics to treat this disease were put into place. An increasingly larger repertoire of drug-resistant strains necessitated and increasingly larger arsenal of drugs to treat the disease. As of today, TB strains resistant to one of the first line of four antibiotics are called resistant strains. Strains resistant to two first-line antibiotics are called multi-drug resistant strains of TB or MDR-TB. These are treated with a second line of antibiotics, consisting of fluoroquinolones (levofloxacin, moxifloxacin, and gatifloxacin) or injectable drugs such as amikacin, kanamycin, and streptomycin. More recently, the third category of strains labeled Extensively drug-resistant- or XDR-TB has been described with resistance to a fluoroquinolone and at least one of three injectable drugs. A total of 12 drugs are approved today, each of which individually and in combination is used to treat these three categories of TB, MDR-TB, and XDR-TB. However, a little characterized fourth type of strain dubbed totally drug-resistant- or TDR-TB has been reported in India, Italy, Iran, and South Africa. These strains are completely resistant to all known anti-TB medication and given the airborne and infectious nature of the disease, are ticking time bombs of catastrophe.

Also Read:
Integrating Technologies To Better Healthcare
Medical Devices In India Witness Churning

Newer Strategies in TB Healthcare

The emergence of drug resistance, the persistently high rate of TB incidence and TB mortality and the challenges associated with patient non-compliance demand improved methods to detect TB with high accuracy, newer drugs to treat resistant forms of TB and increased awareness of the disease.

Bedaquiline and delamanid are two new drugs for TB that have shown promising results in clinical trials after nearly 40 years of failed attempts. These two drugs have received approval for use in the treatment of MDR- and XDR-TB. Additionally, a new drug combination involving bedaquiline, pretomanid and linezolid is reported to have successfully treated XDR-TB in six months with a lower mortality rate than current treatments. However, these new treatment regimens are yet to enter mainstream clinical practice, with further and larger clinical trials needed to make an accurate cost-benefit analysis of these strategies.

Looking to the Future

Although the current situation of TB in India and worldwide looks bleak, the global TB incidence is falling at a rate of 2% per year. According to WHO, this rate needs to increase to 5% to achieve the WHO Global Plan to End TB milestones of reaching 90% of all people with TB through national TB programmes, reaching at least 90% of vulnerable high-risk population through affordable treatment and achieve at least 90% success in the treatment of all people diagnosed with TB. Achieving both WHO and RNTCP milestones will require a concerted effort by policymakers, healthcare providers, TB researchers, patients, and the general public. What we need today is increased public spending on healthcare to make TB therapy affordable and accessible, improvement of research funding and infrastructure and stronger public awareness campaigns to disseminate the reality and requirements of ending TB.

Over just the past two centuries, TB is estimated to have killed 1 billion people, which is more than the number of people killed due to AIDS, cholera, influenza, plague, and smallpox combined! It is time we take the initiative and responsibility to help the millions that are suffering from this deadly disease.

About the Author

Vignesh Narayan is a scientist and science writer at the Indian Institute of Science who currently studies the molecular biology of the TB pathogen Mycobacterium tuberculosis in an attempt to understand how the bacterium senses and responds to its environment and develop new drugs and drug targets to combat the disease.

(Hony) Brigadier Dr Arvind Lal with his keynote address described that only 10% of overall healthcare constituents diagnosis.He discussed the emerging trends in Diagnostics by putting forward four questions

• What is happening in healthcare?
• How will that affect us as pathologists?
• What are the emerging technologies?
• What can you do to better prepare yourself?

[vc_single_image image=”4828″ img_size=”500×300″ alignment=”center” onclick=”link_image”]

Many trends relate to technological advances & the necessity to increase quality & efficiency. The new factor for the IVD industry, not previously seen, is the influence of educated & informed healthcare consumers. Clinical lab testing is one of the greatest bargains in healthcare but often draws the attention from cost-cutters. Lab professionals also will increasingly capitalize on these emerging opportunities & options.

The whole paradigm of healthcare is shifting and will continue to shift—from technological advances like electronic health records. This will change the historic doctor/patient relationship marking the onset of an era of patient empowerment in which the patient shall become more responsible for maintaining good health.

The Healthcare sector, in India, is at an inflection point and is poised for rapid growth At a CAGR of 21% – we will have an industry of 300 billion US $ by 2020. A combination of demographic and economic factors is expected to drive the growth of the sector.

The main points addressed the need to use the emerging trends in diagnostics such as

• Wellness Health Model – the power of diagnostics to change the focus of healthcare from treating sickness to promoting wellness
• The rise of the corporation – Consolidation & Automation
• Role of PPP in Rural Healthcare – a private-private partnership
• Need for Accreditation – Quality of samples and testing
• Consumer-centric healthcare – Handheld devices and POC (Point of Care) testing
• Growing in Digitisation

Dr. Ravi Gaur wanted the healthcare facilities available in metro cities should reach the remote areas too, that’s where innovations in diagnosis should take us. Dr. Vidur Mahajan’s company validates clinical test with their expertise and team of researches.

“Simple solutions for complex problems” is the lateral thinking behind Pawan Asalapuram who is currently working on eradication of TB in the country by his innovations in diagnosis methods. Use of his product, PCR, TB can be recognized in just 90 mins which usually takes 3 to 6 months.

[vc_single_image image=”4830″ img_size=”500×400″ alignment=”center” onclick=”link_image”]

Dr. Richa Dayal suggested continuous monitoring devices. She then spoke on the data analysis part, where the study shows that India is researching on the data outsourced instead of self-published data as we lack in data. She demanded the support of policymakers in the area of diagnostics.

Mr. Anoop Shaji, final year undergraduate student He has delivered dozens of award-winning scientific presentations at various international, national scientific meets on his original novel, indigenously developed, potentially promising conceptual models. Anoop Shaji was the only dental student selected among 160 students all over India from all UG streams to be invited as a delegate to first ever Nobel prize series in connection to vibrant Gujarat 2017, which was presided by 9 Nobel laureates and the prime minister of India for conceptually developing a potential breakthrough for brain cancer treatment.

He became the voice of the young innovators in the conference and emphasized on POC (point of care) diagnosis. His current work is on a simple device detection of cancer with just one single drop of blood. Lab on the chip would be a boon in advancements in diagnostics and insisted on continuous efforts on it along with the financial and legal support.